Tags

Type your tag names separated by a space and hit enter

Short contact therapy with tazarotene in psoriasis vulgaris.
Dermatology 2006; 212(3):235-7D

Abstract

BACKGROUND

We present the results of a multicentre, not controlled, clinical study on the tolerability and efficacy of tazarotene gel, used as short contact therapy (SCT), in psoriasis vulgaris.

OBJECTIVE

To evaluate whether irritant contact dermatitis caused by tazarotene was less frequent and/or less severe with SCT than with traditional therapy, and whether SCT with tazarotene was as effective as traditional therapy.

METHODS

Forty-three patients with plaque psoriasis were treated by SCT with 0.1% tazarotene gel (once daily application for 20 min, followed by washing with water). Treatment duration was 45 days.

RESULTS

Irritant contact dermatitis caused by tazarotene used as SCT was much less frequent and severe than traditional treatment with the same drug. SCT with tazarotene was effective in the treatment of plaque psoriasis.

CONCLUSION

Tazarotene, used as SCT, was better tolerated than the same drug used as traditional treatment. Furthermore, SCT appeared to be as effective as traditional therapy with the same drug.

Authors+Show Affiliations

Institute of Dermatological Sciences, IRCCS, University of Milan, Milan, Italy. stefano.veraldi@libero.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

16549919

Citation

Veraldi, Stefano, et al. "Short Contact Therapy With Tazarotene in Psoriasis Vulgaris." Dermatology (Basel, Switzerland), vol. 212, no. 3, 2006, pp. 235-7.
Veraldi S, Caputo R, Pacifico A, et al. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology (Basel). 2006;212(3):235-7.
Veraldi, S., Caputo, R., Pacifico, A., Peris, K., Soda, R., & Chimenti, S. (2006). Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology (Basel, Switzerland), 212(3), pp. 235-7.
Veraldi S, et al. Short Contact Therapy With Tazarotene in Psoriasis Vulgaris. Dermatology (Basel). 2006;212(3):235-7. PubMed PMID: 16549919.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short contact therapy with tazarotene in psoriasis vulgaris. AU - Veraldi,Stefano, AU - Caputo,Ruggero, AU - Pacifico,Alessia, AU - Peris,Ketty, AU - Soda,Rosario, AU - Chimenti,Sergio, PY - 2005/03/29/received PY - 2005/09/10/accepted PY - 2006/3/22/pubmed PY - 2006/8/31/medline PY - 2006/3/22/entrez SP - 235 EP - 7 JF - Dermatology (Basel, Switzerland) JO - Dermatology (Basel) VL - 212 IS - 3 N2 - BACKGROUND: We present the results of a multicentre, not controlled, clinical study on the tolerability and efficacy of tazarotene gel, used as short contact therapy (SCT), in psoriasis vulgaris. OBJECTIVE: To evaluate whether irritant contact dermatitis caused by tazarotene was less frequent and/or less severe with SCT than with traditional therapy, and whether SCT with tazarotene was as effective as traditional therapy. METHODS: Forty-three patients with plaque psoriasis were treated by SCT with 0.1% tazarotene gel (once daily application for 20 min, followed by washing with water). Treatment duration was 45 days. RESULTS: Irritant contact dermatitis caused by tazarotene used as SCT was much less frequent and severe than traditional treatment with the same drug. SCT with tazarotene was effective in the treatment of plaque psoriasis. CONCLUSION: Tazarotene, used as SCT, was better tolerated than the same drug used as traditional treatment. Furthermore, SCT appeared to be as effective as traditional therapy with the same drug. SN - 1018-8665 UR - https://www.unboundmedicine.com/medline/citation/16549919/full_citation L2 - https://www.karger.com?DOI=10.1159/000091250 DB - PRIME DP - Unbound Medicine ER -